Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 33Leukemia, Lymphocytic, Chronic, B-Cell 31Lymphoma, Mantle-Cell 26Waldenstrom Macroglobulinemia 18Lymphoma, Follicular 18Lymphoma, B-Cell, Marginal Zone 16Recurrence 12Lymphoma 12Lymphoma, B-Cell 9Lymphoma, Non-Hodgkin 6Leukemia 4B-cell Malignancies 3Hematologic Neoplasms 2Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mature B-Cell Malignancies 1Lymphoma, T-Cell 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, B-Cell 1Intraocular Lymphoma 1Hematologic Diseases 1Dendritic Cell Sarcoma, Interdigitating 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 40fludarabine 36fludarabine phosphate 28Tacrolimus 20Whole-Body Irradiation 18Mycophenolic Acid 18Busulfan 18Melphalan 16thymoglobulin 14Rituximab 13Antilymphocyte Serum 12venetoclax 11Thiotepa 10Nivolumab 9Methotrexate 9Granulocyte Colony-Stimulating Factor 9Stem Cell Transplantation 8Peripheral Blood Stem Cell Transplantation 8Cyclosporine 8trametinib 7Sirolimus 7Cytarabine 7Azacitidine 7AP 1903 reagent 7Filgrastim 6Dexamethasone 6aldesleukin 5Mesna 5Ipilimumab 5Interleukin-2 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Neoplasms × zanubrutinib × Lymphoid × Clear all
NCT05665530 2026-01-26

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Prelude Therapeutics

Phase 1 Completed
86 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06697184 2025-12-17

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

BeOne Medicines

Phase 1/2 Active not recruiting
56 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡